Circulating tumor DNA (ctDNA) enables dynamic monitoring of RAS mutations during anti-EGFR therapy, capturing on-treatment clonal selection and re-sensitization after drug withdrawal (Parseghian et al, 2019). Here, EGFR is linked to neoplasm.